头孢布烯-阿维巴坦(固定4 μg/mL)MIC质控范围的测定
本研究按CLSI M23(2018)二级肉汤微量稀释法,为新型口服复方头孢布烯-阿维巴坦(ARX-1796为阿维巴坦前药)建立MIC质控范围。CLSI抗菌药物敏感性试验小组委员会于2022年1月批准了大肠埃希菌ATCC 25922、NCTC 13353及肺炎克雷伯菌ATCC 700603、BAA-1705、BAA-2814的质控范围。
要点
- CLSI于2022年1月批准头孢布烯-阿维巴坦对5株标准菌的MIC质控范围。
- 质控范围按菌株分别为0.016/4至0.5/4 μg/mL不等。
- 该质控范围将支持后续临床开发、器械厂商和常规患者诊疗。
核心结论
- CLSI已批准头孢布烯-阿维巴坦对大肠埃希菌和肺炎克雷伯菌标准菌株的肉汤微量稀释法MIC质控范围。
研究设计与样本
- 按CLSI M23(2018)二级肉汤微量稀释质控研究设计,评估头孢布烯-阿维巴坦的MIC质控范围。
主要发现
- 大肠埃希菌ATCC 25922质控范围为0.016/4至0.12/4 μg/mL。
- 大肠埃希菌NCTC 13353质控范围为0.03/4至0.12/4 μg/mL。
- 肺炎克雷伯菌ATCC 700603质控范围为0.06/4至0.25/4 μg/mL。
- 肺炎克雷伯菌ATCC BAA-1705质控范围为0.03/4至0.25/4 μg/mL。
- 肺炎克雷伯菌ATCC BAA-2814质控范围为0.12/4至0.5/4 μg/mL。
关键数值与推荐
- CLSI抗菌药物敏感性试验小组委员会于2022年1月批准上述质控范围。
- 质控范围以头孢布烯/阿维巴坦固定4 μg/mL组合形式报告。
临床怎么用
- 批准的质控范围可用于支持未来临床开发、器械制造商及常规患者诊疗中的药敏质控。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ceftibuten/ARX-1796 (avibactam prodrug) is a novel oral antibacterial combination in early clinical development for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis. ARX-1796 is the novel avibactam prodrug being combined with ceftibuten for oral dosing that is converted to active avibactam in vivo. A Clinical and Laboratory Standards Institute (CLSI) M23 (2018) tier 2 broth microdilution quality control (QC) study was conducted with ceftibuten-avibactam to establish MIC QC ranges. Ceftibuten-avibactam broth microdilution QC ranges were approved for Escherichia coli ATCC 25922 (0.016/4 to 0.12/4 μg/mL), E. coli NCTC 13353 (0.03/4 to 0.12/4 μg/mL), Klebsiella pneumoniae ATCC 700603 (0.06/4 to 0.25/4 μg/mL), K. pneumoniae ATCC BAA-1705 (0.03/4 to 0.25/4 μg/mL), and K. pneumoniae ATCC BAA-2814 (0.12/4 to 0.5/4 μg/mL) by the CLSI Subcommittee on Antimicrobial Susceptibility Testing in January 2022. Approved ceftibuten-avibactam QC ranges will support future clinical development, device manufacturers, and routine patient care.
引用
- Huband MD, Fedler KA, Sader HS, et al. Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 μg/mL), a Novel β-Lactam/β-Lactamase Inhibitor Combination. J Clin Microbiol. 2023. PMID: 37395644. doi:10.1128/jcm.01657-22
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。